Full Transcript Podcast Intro and Guest Introduction 0:00 To hundred attrition because telomeres are what allows cells to divide. 0:04 We know remember the Hayflick limit there is 200 trillion occurs 0:09 because the cells can't continuously divide forever. 0:12 Up until 1961. 0:14 Most biologists didn't believe that cells could divide 0:16 indefinitely in vitro and in the body. 0:20 And, you know, Doctor Hayflick showed. 0:23 No, that's not the case. 0:24 It was little cells slipping in in the medium into the into the petri dish. 0:28 And then what they were doing these things, 0:29 and that's why they're able to continue propagating. So 0:33 eventually they figured out 0:34 that the clock for this Hayflick limit was the telomere. 0:39 So telomere attrition is a key key component. 0:41 Epigenetic alterations for the next one, which are occurs with, 0:47 you know, 0:49 when the DNA methylation changes and then the access to. 0:53 Welcome to Doctor Talks, the podcast where every episode leads to a healthier you. 0:58 Join us as we navigate the world of optimal health, 1:01 uncovering groundbreaking strategies to conquer chronic disease. 1:05 In each episode, we'll bring you the latest insights 1:08 from leading health experts, medical innovators, and wellness warriors. 1:12 If you're seeking to transform your health journey, or if you're looking 1:16 for answers to burning questions, you've come to the right place. 1:20 Get ready to unlock the secrets of lifelong health and vitality. 1:24 This is Doctor Talks, 1:26 real talk from real doctors on the issues that matter to you most. 1:32 Follows Doctor Ken Holter with another episode. 1:34 Today. 1:35 We have the luxury, but we've been having Doctor Rafael and he's gonna be talking 1:40 about the role of telomere biology and age management medicine. 1:46 Doctor Rafael, thank you so much for being on and taking the time. 1:49 I know you're busy guy, extending people's lives. 1:53 And, so it's great to have you. 1:55 I'm looking forward to learning a lot about longevity and ways to do that. 2:01 Well, thank you, Doctor Holdsworth. 2:01 I'm happy to be on and happy 2:03 to talk about one of my major passions in life, which is keeping people 2:07 healthy, and doing what they love to do as long as possible. 2:10 And I love the fact. 2:12 And we'll get into this how, you know, you don't just do this of you 2:16 show the people and document that they are actually younger. 2:21 Yeah. 2:21 I mean, we measure. 2:23 Well, one of my major focuses is to measure the aging process in people 2:28 at baseline to see what their strong systems are, 2:31 because we all are a mixture of weak systems and strong systems, 2:34 and you have to focus on the weaker ones and try to shore up the stronger ones. 2:40 And we really want to, 2:41 to sort of know once we start therapies, whether they're effective. 2:45 It all started back in it was 2001 when Bob Butler, 2:49 if you remember him, he was the founder of the National Institutes of Aging,
Measuring Aging and the Origins of Age Management Medicine 2:52 convened a roundtable. 2:53 And I had been practicing 2:56 what was going under the rubric of anti-aging medicine at that time. 2:59 I mean, hormone replacement therapy, testosterone for men, and then, growth 3:04 hormone replacement therapy and patients were doing well, fairly well. 3:07 But at the same time, the NIH was looking at studies, 3:09 looking at biomarkers 3:10 of aging to see whether there was any way to measure whether or not these 3:13 these therapies were being effective. 3:15 And he invited me to a roundtable 3:16 with a number of relatively illustrious, gerontologist. 3:21 And it was sort of like being invited as a sacrificial lamb to this thing 3:24 where they're going to tell me, why are you doing this stuff? 3:26 You're killing these patients. 3:27 And and what came out of it really was it wasn't quite as bad as that. 3:31 But when he said, look, you're a smart guy, Joe. 3:34 What you're doing seems to be helping your patients. 3:36 They feel well. 3:37 But how do you know if you're actually, 3:40 you know, calling yourself an anti-aging doctor? 3:41 How do you know if you're actually altering the aging process 3:43 and sort of a little light went off in my head. 3:45 I've been doing this about four years, 3:46 and I thought I was doing pretty good stuff for my patients, 3:48 but that started me on this journey of looking at the literature 3:52 for what was available to measure, how people age, 3:55 whether or not we could see whether 3:56 these things that we're doing for them are actually altering their aging process. 4:00 You know, either you know, a good or a bad way. 4:02 And that's been one of my passions since then. 4:04 And, you know, thank Bob, who has since passed away, for 4:09 for getting me started on that, because it's a fascinating field 4:11 of so much literature out there about it. 4:13 You know, one of the areas that then later and probably about to, 4:17 you know, 4:18 I really standard medicine moving very fast in this area, you know, 4:23 but acute but, just a little formal stuff. 4:27 But Doctor Rafael, he received his BA in philosophy. 4:31 Very nice and Princeton, no doubt his M.D. 4:34 from Drexel University Medical Center. 4:37 He trained at the New York University Hospital. 4:39 Cornell University Medical Center was formerly 4:41 a clinical assistant professor of medicine at Dartmouth Medical School. 4:46 I practice the at the Hitchcock Clinic. 4:49 He's a member of the Endocrine Society, is board certified internal medicine 4:54 and as defined by the American Board of Anti-Aging medicine. 4:57 Or are you an endocrinologist or. 4:58 No, no, I do a lot in terminology, but I'm not an endocrinologist. 5:02 Yeah, yeah, I'd say I'm a member of the society. 5:05 But I stopped going to their conferences because it's the same stuff over and over. 5:10 It's just like they're arguing the same points that they were 15 years ago. 5:14 I would agree with the other guy. 5:15 I went for probably between 1995 and 2015, 5:21 I went to virtually every major meeting, every every, every annual meeting. 5:24 But I think that 5:25 and there's a lot of good science that takes place there, but they're stuck in 5:28 not thinking about optimization, but about disease. 5:31 And that's really not what we're about. 5:33 And, you know, biological variables are continuous. 5:36 A testosterone of 301 is not different from a testosterone 299. 5:40 Yeah. 5:41 Your cut off is 300. 5:42 Yeah. 5:43 No arguing what the age normal should be. 5:47 It's like but even though with all its flaws and I went 5:50 because the top guy in terms of thyroid replacement and pregnancy was there 5:56 and I said I can't find a study shows that T3 crosses the placenta. 6:00 You know, I don't know if you know. Yeah. 6:02 And that which we know it does. 6:04 Do we have people on straight down three that have great babies? 6:07 But anyways, so what about Doctor Rafael? 6:09 In 1997, he co-founded the Physio Medical Group or exclusively practice age 6:15 management medicine, with a focus on personalized hormone optimization. 6:19 Physiological age assessment. 6:21 In 2007, he co-founded the Physio Age Systems, 6:25 a web based biomarker data collection reporting system. 6:28 Now use use by age bands and functional medicine practices around the world 6:32 to assess, monitor, communicate the patients effectiveness of a treatment. 6:36 So we'll get into that about, you know, really testing people's age, 6:41 not just giving a message. It's good for you. 6:43 You know, you can take 10,000 supplements that people say are good for you. 6:47 So 2009 is involved in clinical telomere biology 6:50 research is published three studies on the effects 6:53 of oral telomerase activators on normal aging adults. 6:57 He has lectured nationally internationally because of application telomere biology. 7:01 In 2015, 7:02 he found that Rafael all medical group and blogs reviewed about 7:06 telling their biology about optimization and biomarkers of aging. 7:10 UN Rafael medical.com RAF 7:14 a weekly medical.com 7:18 and physio age.com physio aging.com. 7:23 Yeah well yeah welcome and can't wait to kind of get into the meat here and 7:28 and pick your brain and share with our our viewers and physicians 7:34 and some of the intelligent lay public about all the stuff that you know 7:38 and that you've been doing. 7:40 So, so you've been practicing by 25 years, kind of like me. 7:43 It goes by so fast, really goes. 7:46 Yeah, it's crazy. 7:48 And so you've been doing you've been focused on this age management 7:52 jump the whole time or. 7:54 Yeah, I mean when I for five years I practiced practicing for 30 years, 7:58 actually for five years I practiced internal medicine, as you mentioned. 8:01 And Hitchcock system up in New Hampshire when I moved up there right 8:04 after residency and sort of got my doctor legs taking care of my eyes 8:08 and, you know, pneumonia and all the things you do 8:10 in a primary care internal medicine practice 8:13 while I was also, you know, on the assistant clinical faculty. 8:16 So, but at the end of the five years, I had kind of aging parents, 8:21 I was a little bit, my parents a little older when they had me. 8:23 So they were starting to age significantly, 8:25 and I sort of wondered what I could do to help them to, to age better. 8:28 And that started me thinking that, you know what? 8:31 This isn't really the thing to do is putting Band-Aids on all these things, 8:34 waiting for the diseases occur. 8:36 So that really made me sort of open up a practice. 8:40 Moved back down to New York City and open up a practice 8:42 looking at how to slow down the aging process and, 8:45 keep people as healthy as long as possible. 8:49 Interesting. 8:49 And just a side note, have you found, like. 8:52 Well, I found some of these elite athletes who you think 8:56 are the the ultimate in health, and they actually turn out 9:01 to have lower, higher biological ages than normal. 9:06 Yeah, I see that. Absolutely. 9:08 I mean, there's there's 9:10 you know, I hear about these people 9:11 that have do things like, you know, a marathon a week or a marathon 9:15 a weekend, like every state, you know, and a 50 in a row in 50 weeks. 9:19 I'm like, that's just not good for you.
Hallmarks of Aging and Telomere Biology 9:22 There are people who have some in, you know, some genetics that can 9:25 get them through that. 9:26 But that's in the end, just too much of a stress on the body. 9:30 And you see that kind of stuff. 9:32 Oxidative exercise is great for you 9:34 to the extent that you that allow yourself 9:35 to recover, there's damage during the exercise. 9:37 And the recovery builds you back stronger. 9:39 But if you're breaking yourself down all the time 9:41 and this gets back to, you know, to, to really into, into telomere biology, where, 9:45 you know, your stem cells have to replenish those degenerated tissues 9:48 and have to keep on because they're being asked to divide a much higher rate 9:52 because the damage is occurring at a higher rate. 9:54 Then at a certain point, their telomeres get too short 9:57 and they can't do it anymore. 9:59 So I think that I absolutely see that kind of stuff. 10:01 You know, I have a guy will come in and, well, his cardio age away. 10:06 We measure their central arterial pressure and give them an age for how healthy 10:09 they are. 10:09 The elasticity of their arteries is might be great. 10:12 Something like their immune function or their telomere length 10:15 won't be as good because they're putting a lot of stress 10:18 on their body with training. 10:19 And it varies. 10:20 Some, some people have we'll talk about the heritability of telomeres. 10:24 Some people have a lot more reserve. 10:25 They have more money in the bank 10:27 and they can get away with that and others don't. 10:29 And there's a wide variability 10:30 in what you inherit in terms of your telomere length. 10:32 So giving them that kind of information is really actionable. 10:35 Yeah. 10:36 And as it's almost harder 10:37 to have them reduce their exercise than people to get them to exercise. 10:41 So it does it seems like it makes sense that they become like a chronic illness 10:46 if it's just constantly under stress and right, and break it down. 10:50 Yeah, absolutely. 10:52 And so in terms of telomere biology, 10:56 how long have you been releasing that you you published on that? 11:01 And what's your thought on telomere versus other methods. 11:05 And I know use a lot of things, which is the way to go. 11:08 And that's like the way we assess, let's say a sick patient line kind of know 11:13 we love to get a ton of labs and it paints a picture like no one 11:17 marker can just lead you astray, you know, oh, you're fine. 11:21 This is good, you know? So I can totally see that. 11:24 And I can see where your software program can be a big benefit to. 11:28 Yeah. 11:28 So it really, I think I when I first started 11:31 looking at biomarkers and I think when the Nia and other people, you know, 11:35 gerontologist started looking, they were looking for a single biomarker 11:38 that could encompass the aging process in toto 11:42 and sort of predict who was going to die younger or older based on this biomarker. 11:48 And in fact, the NIH and the NIH, after ten years of looking for that 11:51 in identical strains of mice, said they couldn't find one like that. 11:54 And I think they were just setting the bar too high. 11:57 And then since then, what you see is the newest kid on the block coming out, 12:00 and then they say, well, okay, it's telomere biology. 12:04 And then so you want to measure telomere length. 12:06 And then the epigenetic age people come in, they say no, 12:09 this is more correlated with age. 12:10 And so telomere biology doesn't make any difference. 12:12 And then you see 12:13 you know the proteome people coming in or the microbiome people coming in. 12:17 And the truth is they all give information that's important and and is useful. 12:22 And as you say in painting a picture of what's going on, I mean, I think 12:26 what's really happening is, is that we're understanding 12:28 for aging in particular, that systems biology is what has to be applied. 12:32 And that means looking at multiple markers in multiple systems 12:36 from many different angles. 12:38 And then applying, you know, deep learning, artificial intelligence to it 12:42 to try to really understand what's happening 12:44 and to think that a single biomarker is going to tell you, you know, 12:47 what's going to happen and who's going to have, 12:49 you know, who's going to die at a certain time, much less 12:51 what state of health they're going to be in between now 12:53 and then is, I think, kind of silly, really, when you think about how complex 12:57 the human body is and how it ages. 12:59 So, you know, I got introduced, we were all doing hormone optimization, 13:02 and we had the big kick up of the Women's Health Initiative that then actually 13:06 was very good for my practice because of all the misinformation out there. 13:10 So I was helping women sort of navigate that for a lot. 13:13 That was the biggest disaster, poorly designed, like, oh, yeah, cause 13:17 I think there's estimated 13:19 50,000 deaths of women because of cardiovascular disease 13:21 for not being put on hormone replacement therapy. 13:23 So it was it even lingers today, which is just insane because it's been 13:27 oh, I hear it all the time. 13:29 Don't you guys get breast cancer? 13:31 Yeah, exactly. 13:34 So so where was I going with it? 13:39 So we started 13:40 I just started to, to to to get into tutor biology when I was 13:44 introduced to it by Neil Patton, the start, the founder of sciences, 13:48 who came to my practice and said, what would you what would you take? 13:51 What would it take for you to sort of recommend this to your patients? 13:53 I said, look, you know, I'm I'm I'm an evidence based doctor. 13:56 I have these biomarkers of aging, and the biology is fascinating. 14:00 And I think the telomeres, you know, subsequently have, 14:02 you know, they're one of the the four major hallmarks of aging. 14:05 There's nine of them. It's one of the top four. 14:07 And so I said, look, if you're willing to have patients 14:11 come through and get all the biomarkers, we'll track them for a year 14:13 and see what happens with them. 14:15 And that's what we did. 14:15 And that was that was the, 14:17 the beginning of the first publication that we had for, for to sciences, 14:20 and the effect of the summer is activator to 65. 14:24 So that got me started in looking at the biomarkers. 14:27 See what what agent that has the tropic effects because it 14:30 affects stem cells and immune system, what that has on the rest of the body. 14:34 And you know, so that's I think that's sort of the path that way. 14:37 Nice nice. 14:39 And so you mentioned kind of nine hallmarks of aging. 14:43 Can you talk more about that. 14:46 Yeah. 14:46 So that you know, so I think aging the aging field has been 14:51 you know, I think at one point there was papers 14:52 published that there's maybe 200 different theories of aging. 14:55 I remember War Dean was one of the fathers 14:57 of this sort of back in, back in the late 80s, early 90s. 15:01 And everyone was trying to figure out what exactly, you know, was 15:05 what was going on, the aging process. 15:06 Is there a single underlying aging process? 15:08 And in 2013, I believe there was a paper published by Lopez 15:12 or teen and and Maria Blasco and other people are major figures in the field 15:18 which had been predated a little bit by Aubrey Debray. 15:21 The, the the Gray's paper about hallmarks of aging as well. 15:25 But I think that the field now the sort of gerontology field agrees 15:30 that there are sort of nine major hallmarks of aging, 15:33 you know, genomic instability, telomere attrition, epigenetic. 15:36 You can can you go slower on that? 15:38 Oh, okay. 15:39 Yeah. 15:39 So, so the the nine maybe we go through. 15:42 All right. 15:43 Now the top four are the first one is genomic instability. 15:46 That is we all know about what happens. 15:49 The genome gets attacked by free radicals. 15:51 And the copying is is you know, there's 10,000 hits per day to 15:55 to the DNA in every cell. 15:57 And that's denim. 15:58 Hardin's sort of free radical theory of aging kind of thing. 16:02 And then there is telomere attrition 16:04 because telomeres are what allow cells to divide. 16:08 We know the Hayflick limit. 16:10 There is telomere attrition occurs because the cells can't continuously 16:14 divide forever. 16:15 Up until 1961, most biologists didn't believe that cells 16:19 could divide indefinitely in vitro and in the body. 16:23 And, you know, Doctor Hayflick showed that. 16:26 No, that's not the case. 16:28 There was little cells slipping in, in the medium 16:30 into the into the petri dish. And they were doing these things. 16:33 And that's why they're able to continue propagating. So 16:37 eventually they figured out 16:37 that the clock for this Hayflick limit was the telomere. 16:42 So telomere attrition is a key key component. 16:45 Epigenetic alterations. 16:46 But the next one which are occurs with, 16:50 you know, when the DNA methylation changes 16:54 and then the access to, to to DNA changes or gene expression changes, you know, 17:00 Michael Fossil, who is one of the smarter guys that I know is one of the preeminent 17:04 telomere biologists, likes to talk about the fact that the genes in your nose 17:09 are the same as the genes in your toes, but you know what makes it toto? 17:12 And it knows it knows it's gene expression. 17:15 And so obviously gene expression changes during development. 17:18 But the same gene expression takes place changes during aging. 17:23 And it and, you know, Steve Horvath has shown 17:25 in his elegant series of studies that in fact, it's so tightly, 17:29 you know, when you look at certain CPGs, it's so tightly 17:33 correlated with age that you can use it in forensics almost, but, 17:36 to, to figure out, you know, what what the. 17:37 Yeah, I think you have a very interesting point. 17:40 It's because, yeah, you do have the same genes everywhere, right? 17:44 But yeah, all the different parts are doing different things. 17:48 And, and you know, the basically epigenetics and that's like 17:52 we're a lot of peptides. 17:53 They'll show they'll turn on 45 genes and turn off 2016 that they know of 17:58 and a lot of variable flavonoids, you know, which I love. 18:04 But yeah keep going. 18:06 Yeah. 18:06 I mean, so I mean that's 18:07 I think the same thing that takes place doing development takes place in aging. 18:11 And, and so there's an aging youthful gene expression and there's a more aged. 18:15 And then there's an old gene expression. 18:17 And, you know, that shows that there is malleability to the aging process. 18:21 If you can turn back and there's, you know, there was a early study, 18:24 a recent study looking at turning back the epigenetic clock 18:27 with growth hormone DHEA and at Foreman, the Trim trial. 18:30 So I think that obviously 18:33 gene expression is a major marker in question for you. 18:36 Just about, you know, growth hormone, anti-aging people use growth hormone. 18:41 But it's shown to help like no studies shown giving regiment causes cancer. 18:46 Whichever one brings up. 18:47 But the longest live people seem to have like low IGF one. 18:53 How do you reconcile that? 18:58 Yeah, that's a very complex area. 19:00 I mean, I think that, you know, if you look at if you if you talk to, 19:03 and those are those are very good points. 19:07 There's a I think there's a little bit of a trade off 19:09 between function performance and potentially aging. 19:12 And some of these, you know, 19:13 the old, old that they study in the shows, some of them have lower IGF one. 19:18 I mean, I don't necessarily want to be like that one. 19:20 I'm that age. 19:21 I mean, I think that the animal models that they look at 19:24 where it TF1 is a growth hormone way overexpress these transgenic mice. 19:28 I mean, we know what happens 19:29 when you have way too much growth and when it's acromegaly. 19:31 Most people don't live long. 19:32 They get big hearts, big jaws. 19:34 They have other issues. So we don't want that. 19:37 The real study that no one is rich enough to have that happen to them. 19:41 Right? Right. Exactly. 19:43 You need a lot of growth hormone down there. 19:45 And you know what? That I think. 19:47 But then they do look at these studies in the mouse models 19:50 and they and they say, you know, the IGF one turns up is a pro aging form. 19:55 It's also a pro performance. 19:57 I mean, we know that higher levels of IGF 19:59 one are associated with better levels of cognition. 20:01 So the question is is, is is in the aging adult 20:05 is keeping growth hormone and IGF one levels in the more 20:09 youthful physiologic range in the aggregate beneficial? 20:13 There's no study that speaks to that. 20:15 We just 20:16 you know, the NIH did short term studies and there wasn't any increased 20:18 risk of cancer. 20:19 And I can see that in in a year long study, there was some improvement 20:23 in lean body mass, but there wasn't long enough to know 20:25 whether overall it's going to affect the aging process. 20:29 One of the reasons growth hormone 20:30 is, is because as long term is approved for long term therapy 20:33 and growth hormone deficient adults, 20:34 it becomes a 2 to 3 fold increased risk of cardiovascular disease that you have. 20:38 If you are if you have a very low IGF one for a long time. 20:41 So the the growth hormone story and IGF one story, aging is just another 20:46 is a sort of evidence that you have to look at the whole picture. 20:49 You have to look at. 20:50 All right. 20:50 So you're diving deep into peptides and longevity on this podcast. 20:54 And we're right there with you. 20:55 Integrative peptide stands out trusted by over 20:58 10,000 doctors to deliver real results for their patients.
Growth Hormone, Hormones, and Personalized Optimization 21:02 These premium peptides are your key to unlocking 21:05 vitality recovery and a longer, stronger life. 21:09 Visit Integrative peptides.com and use the code 21:12 Pod life for 10% off your first order. 21:15 Again, integrative peptides.com. 21:17 Use the code pipeline for 10% off. 21:21 It's time to elevate your journey starting now 21:25 with a like. 21:26 Look at all the studies and sick patients and just AG. 21:29 When you look at even evolution of the thymus, I 21:32 it you know everyone has hypothalamic pituitary dysfunction. 21:35 So really in the modern world toxins pesticides stress chronic infections. 21:41 Your gut dysbiosis is going to suppress that. 21:45 You know we have now you know kids 21:48 coming in at you know 25 and their testosterone 21:52 levels like 200W, like that of a nine year old growth 21:56 hormone is super low, you know, so like, how can that be healthy? 22:02 You know, it's not I mean, if you look at them and, you know, 22:05 I've been treating patients with growth hormone for, like I said, 25 years. 22:09 And you know, 22:11 you have to look at each patient individually and you have to 22:14 you say, look, okay, if your IGF one is below 150 22:17 and you're having trouble with abdominal fat, you know, your exercise 22:21 in giving growth hormone fixes the abdominal fat, brings the IGF one up. 22:25 Then you're set into motion 22:27 a whole bunch of beneficial things that insulin resistance reduces. 22:31 And so it's it's got a lot of hype, both in the negative and in the positive. 22:36 And the truth is it's just another one of the hormones that's important. 22:39 Not everybody needs it. Some people do, some people don't. 22:42 And that's the way I practice. 22:43 The problem too is you look at, you know, reference ranges. 22:47 So I'll take 95% of the people, like take testosterone, for instance. 22:51 It's like your decade ago ranges were higher 22:55 and decade for that they were higher. 22:58 So now it's like they lead especially with growth hormone 23:01 like the lower limit of normal is like the person would be. 23:06 Seems like they're going to be dead. 23:08 You know. 23:10 Yeah I mean it's crazy. 23:12 Yeah. 23:12 So but to sort of bring it back to telomeres, 23:15 I mean that growth hormone is important because you know what it does. 23:18 It muscles, it stimulates muscle satellite cells which are the stem 23:20 cells and muscles to divide, which then can be worked on by testosterone 23:25 to get it to get bigger for hypertrophy, hyperplasia and hypertrophy. 23:29 But if you're stimulating the muscle stem cells to divide more rapidly 23:33 with growth hormone, you got to make sure they got telomeres. 23:35 You can do that. 23:36 So that's what I think that to me your biology dovetails very nicely 23:40 with hormone optimization and knowing whether or not someone has adequate 23:45 telomere reserve to be able to take the the increased stimulation. 23:50 And for cell division that the hormones give you is is important. 23:53 I mean, I haven't done the study, but the hypothesis is that perhaps, you know, 23:56 some of the risk which I aggregate is either none or very, very, very little. 24:02 I've increased risk of breast cancer may be localized in those women 24:05 who have very short tumors, because very short telomeres, 24:09 unequivocally associated with increased risk 24:11 of, of cancer of many different kinds of epithelial cancers. 24:15 So, so that's why I now when I measure 24:18 hormone telomere length of all my patients that I want to know what's happening. 24:22 Because if to deliver lines get to short the cells then 24:25 then they get genomic instability and they become much more likely 24:28 to become cancer cells. Interesting. 24:30 And yeah, BPC 157 actually increases growth around receptors on the cell. 24:35 And now in terms of telomeres 24:38 is the what's more important, the average length or the percent of short 24:44 telomeres or it can you just get. 24:48 Yeah, that's a good question a great question. 24:49 I mean, 24:50 the vast majority of the data on tumor length 24:53 and health and disease is using mean telomere length. 24:57 And so that's still a useful, a useful measure for 25:01 for looking at where somebody is. 25:03 But it is pretty well established that it is 25:06 the shortest telomere within the cell that causes the cell 25:10 to go to become senescent or to go into apoptosis and into crisis. 25:15 And and it could 25:16 you have it can be 2 or 3 short telomeres within the cell that causes that. 25:20 So and we know that telomerase preferentially goes 25:24 and tries to lengthen tumors that are shorter. 25:27 So when in the actual biology of talk of telomere length 25:31 it is the critically short ones. 25:33 But we have to remember when we're measuring telomere length in blood, 25:36 we're measuring telomere length in the in the white blood cells. 25:39 And depending on the technology it's, you know, PBM or 25:43 or if you're using the technology that I use, 25:45 we can break it down to the gray oocytes and lymphocytes. 25:48 That's a surrogate marker for what's going on in other tissues. 25:51 And and there's there's concordance between what's happening 25:55 in the white blood cells and what's happening in other tissues 25:57 with because of, you know, that's been studied. 25:59 But you you want to look at the data, which shows that 26:03 I think that looking at the average telomere 26:05 length does help, you know, whether or not a person is at risk 26:09 and also whether or not the Flubber is activator is working. 26:11 There isn't a really good commercially available short telomere assay. 26:15 Lifelink does have, you know, they give a 20% for 20%, 26:19 but that's really more correlated with the mean telomere length than it is. 26:23 But the critically short telomere length, which are under three kilo bases, 26:26 just to give you sort of an idea for your listeners, telomere length 26:30 by by what we 26:32 call flow Fish is usually somewhere between 8 and 12 kilo 26:36 bases, or 8000 to 12,000 base pairs in length at birth. 26:41 And then you rapidly lose some during the growth phase. 26:45 And then after that it's about 0.05 kilo bases or 50 base pairs per year. 26:50 So that is kind of just sort of an idea about about where you are 26:54 with during your length when, when, when you're when you're when you 26:58 and you kind of answer the question I was going to ask you, like, you know, 27:01 then you're checking telomeres and, you know, white cells 27:04 like what's going on with whatever 27:07 all the think of all different cells in the brain part, whatever. 27:11 They tend to correlate is that. Yeah. 27:14 Let's a on that. Yeah. 27:16 Limited studies I mean not as extensively like because as you can imagine, 27:19 it's not easy to get biopsies of liver and lung and human brain. 27:23 But the studies that have been done show that there is pretty good coordination. 27:27 And the reason for that is because one of the major determinants of your telomere 27:31 length in all your tissues is what you what you inherited from your parents. 27:35 And so that's about 70%. 27:37 That's a it's a very highly heritable trait, which we call it, you know, type. 27:40 So, you know, when it comes to telomeres lifestyle is very important. 27:43 Everything else you're doing. 27:44 But you really want to choose your parents wisely. 27:46 That's really what happens there. 27:48 I mean, the difference between eight kilobyte basis 27:51 and 12 kilo basis of telomere length inheritance is about equivalent 27:55 to the amount of loss that occurs between young adulthood and death. 27:58 So if you start out, you know, at eight, 28:01 you're like pretty far along as compared to somebody who starts out at 12. 28:06 And that's why people have quibbled about whether or not telomere 28:09 length is a useful biomarker of aging, because a seven year 28:13 old can have the same telomere length as a 40 year old. 28:15 And so why is that useful? 28:16 Well, it's useful because we still know that 28:19 when you get down to a certain telomere length, all hell breaks loose. 28:23 And that's around below five kilo bases. 28:26 So, you know, it's a matter of what you inherited and what your attrition like is 28:30 you can't change what you inherited, but you can change the attrition like by. 28:34 That's why telomere length is is junior length is so interesting 28:37 is that pretty much every healthy behavior from lifestyle to exercise to diet 28:42 to supplements, etc., has been shown to slow down telomere 28:46 length loss and pretty much everything that you do is bad smoking, 28:50 high fat being, being overweight, not exercising. 28:53 All those things are associated with shorter telomeres. 28:56 And so it's kind of an integrator of many different what we call Alice. 29:00 Allostatic load or on the body. 29:02 And so if you're doing all the good things that are healthy, 29:07 you might have a slower attrition. 29:08 But if you start out with really short telomeres, it's 29:11 still going to be a problem. 29:12 And you can have a healthy person. 29:15 And I have people that do everything right. 29:16 And and I see that because they track them over time. 29:19 They're not losing telomere length at a very 29:20 but they didn't start out with very good tuner links. 29:23 And so they have to be more careful, you know, don't smoke. 29:26 I mean and it's very behavior modifying as well. 29:29 When you tell somebody that, you know, your tuner is you're 40 29:31 and they're more like a 50 or 60 year old, then they're more likely to be 29:35 more proactive about healthy behaviors because they know that are 401 K. 29:39 I like to call it the biological 401 K. 29:41 Yeah. 29:42 Or, you know, the biological IRA is just not as full 29:45 for their retirement of healthy aging as they get older. 29:49 And the sleep effect telomere length. 29:52 Yeah it does. 29:53 And same way in which I mean, 29:54 I would say that it's not a good biomarker of aging if sleep doesn't affect it. 29:58 So epigenetic aging DNA 30:00 methylation has been shown to be highly affected by poor sleep 30:04 because that's when your body gets into, reparative state and it's this thing. 30:07 So it's definitely sociopath, like, do as I say now as I do. 30:11 And I know I stay up all night to get projects done. 30:15 That's what I work well and I feel like it's aged me, you know, 30:19 and I don't know, the studies on like nightshift workers and telemedicine. 30:24 Is there anything like that? 30:25 Yeah, they're shorter and also, nightshift independent 30:29 and of course would make sense of nature. 30:30 Nightshift workers have increased risk of cardiovascular disease and cancer, 30:34 you know, and it's probably not solely because 30:37 of their general like, but certainly, there's other things that are occurring. 30:40 Vitamin D is associated with telomere length. 30:42 And so if you're a night shift work, you're 30:44 probably not getting as much vitamin D and your body D levels low. 30:47 It's really a it's a very good integrator of many different things, 30:51 but also with the caveat that it depends on what you inherited. 30:55 So one one telomere length measurement gives you some information, 30:59 particularly if it's very short or and also it's very long. 31:02 But what really gives you information is serial measurement. 31:04 Over time you want to see where you're going. Yeah 31:08 what you where you're going. 31:09 And so how much of an increase in C 31:13 with like T 65 or what period of time or with other interventions. 31:19 What are some of your like major things say like this 31:23 is the number one thing I can say about is what they're also people are doing. 31:27 Like what's the worst thing they're doing? 31:28 But like let's say we give someone t 65 when do you recheck 31:34 and what type of response have you seen. 31:37 Yeah. 31:37 So let me start with the,
Telomere Testing, Infections, and Immune Aging 31:40 the clinical studies that we have 31:44 the in the cohort study that I mentioned, we didn't see an actual increase 31:47 in DNA length, but we saw all sorts of improvements in immune system function 31:51 that the reduction senescent cells, which we think had to do with 31:55 decreasing 31:56 the number of shortest telomeres within the cell. 31:59 But that spurred the company on to do a randomized controlled trial 32:03 looking at the effect of to 65 in C, a B positive patients. 32:07 And we found that there was a 533 base pair 32:11 increase of after a year of 65. 32:14 So that's that's a pretty big one. 32:17 Now that was using the technology. 32:18 That is where the average human length is about 40% longer using that technology. 32:24 So you have to take that 533 and make it more like about 300 32:28 a base pairs or 0.3, which is still quite a significant increase. 32:32 And it was highly statistically significant in comparison to placebo, 32:35 which lost to litter length, which of course, you would consider. 32:38 So we do have randomized controlled trial data showing 32:41 that that there is an increase in telomere length with 65 at the doses 32:45 that are normally used, 250 I used the 500 I use, you know, in my practice, 32:50 I've seen patients have actual increase in telomere length over time going up. 32:56 As much as 32:58 half a kilo base or 500 base pairs over a couple of years. 33:02 But what I see most often is, 33:04 is that the law stops and you get, you know, so I myself 33:09 have had telomere length of about 6.4 kilo bases for the last 13 years. 33:15 Which is, you know, 33:17 I would expect over that time period to have lost about 0.8 kilo bases. 33:20 I've gone down to below five. 33:22 And, and that's 33:24 and if you can maintain your telomere length, as I said, 33:26 this is when they get critically short, then it's a problem. 33:28 Then that is really, you know, is quite good. 33:31 It's just like a corner calcium score. 33:33 I mean you don't want to put any calcium score of too high, 33:35 but if it stays at 200 or 400, you're unlikely to have a corner. 33:41 Because and 33:41 and did debate do see me infected patients 33:45 kind of like to speed up that aging. 33:48 The telomere loss really get a better like so you can do a shorter study. 33:53 Not wait 20 years. 33:56 Yeah. 33:56 So the reason, I mean, CMV is a whole nother fascinating thing that, 34:00 that there's whole conferences 34:02 that are convened on be just to, for the for everybody knows 34:05 CMV is herpesvirus five and in, in immuno competent individuals, 34:10 most doctors are like, you know, it's not going to do anything to you. 34:13 Don't worry about it. 34:14 At about 60% of the US population is CMV seropositive 34:18 and it goes up 1% per year starting at ten years of age. 34:22 So by the time we're in the eighth or ninth decade, it's virtually 90 to 34:26 100% CMV positivity. 34:28 But there's an active right it. 34:30 Well, so that's the interesting thing that as with all herpes viruses, 34:33 they sit latent. 34:34 You know, it's the gift that keeps on giving doesn't ever go away. 34:38 And to the extent that there are reactivation there's a problem. 34:41 So when you get a culture that comes out that's herpesvirus one. 34:45 You feel systemically kind of crummy. 34:47 It's not just the culture because there's a whole reactivation of it, 34:50 and that makes your immune system have to rev up to then make it latent again. 34:54 That causes your white cells to have to divide for your lymphocytes 34:57 to have to divide more, and that shortens their telomeres. 35:00 Same thing happens with CMV, except when does reactivation occur. 35:04 There's no real symptoms. 35:05 You might feel a little crummy, maybe a little something, 35:07 but most people don't have any idea that they're having a reactivation. 35:10 And if that occurs over and over and over again, that 35:14 accelerates telomere loss, increases the accumulation of senescent cells, 35:19 which you know, are bad for you because they secrete the what's called the 35:22 senescence associated secretory phenotype. 35:25 All these inflammatory markers like il6, TNF alpha, 35:29 they reduce the production of interferon gamma to fight off viruses. 35:32 So it increases what it causes this state of what we call inflammation. 35:36 So CMV, even in an immuno competent adult eye, 35:41 it causes over time and acceleration of aging of your immune system. 35:46 And we think most other tissues in your body as well. 35:50 You know, there might have been some benefit to it 35:52 in our ancestral environment because it allowed us to 35:55 to potentially have a more robust immune response to pathogens. 36:00 And nobody lived long enough to have the adverse effects, 36:03 something called antagonistic atrophy, where something is good for you 36:06 when you're young but may have other adverse effects when you get older. 36:10 That's that's true of CMV. 36:12 We chose CMV for that, for that trial 36:16 because there is a more acceleration of, of of loss of telomere length in that. 36:21 And because we saw in our cohort that a lot of the benefit 36:24 was in the individuals that were CMV positive within that cohort. 36:28 So subsequently there, you know, we there is a trial that is pending right now 36:32 submitted to OBM geriatrics to look at the effect of 65 on senescent cells. 36:37 And that's, you know, in both, 36:42 can be positive and can be negative. 36:44 And we see a beneficial effect 36:45 in whether you see any positive or seem to be negative. 36:47 Yeah. 36:47 Because I rarely see anyone. 36:49 And I well what test these. 36:51 Because you see I you know IG 36:53 they don't make even a reactivates idea of it's not a new infection. 36:57 And the PCR is from standard labs or so insensitive. 37:01 Let's try I six. 37:03 You know at least Montoya showed a little bit 37:06 of a good study where you know, the reference range is like 1 to 20. 37:11 But really a positive is like 1200, you know, because that's 37:17 what it doesn't mean. 37:18 It's reactive, but it's more likely the higher it is. 37:21 Is that what they did or they do a PCR or what they do with 37:25 for for looking at the CMV. 37:28 No. What. 37:28 So it's just whether you're seeing me positive or negative, that's okay. 37:32 We didn't look at the titer when you're talking about is the titers 37:35 and and yes those in actually in CMV if the higher titer you ha you have, 37:40 the more you have senescent cells because there's more reactivation 37:45 is taking place. 37:46 I mean, I think the CMV is is not unique, but 37:49 it's probably the most immuno dominant in terms of stress in your immune system. 37:53 But pretty much anything that causes you to have to mount a response, 37:58 intracellular pathogens like Lyme and the because just the other things that you're 38:02 mentioning, I have patients that come in that are being treated by Lyme doctors. 38:06 And for chronic Lyme and their telomeres are shorter. 38:08 And what's interesting is 38:09 there's something called the lymphocyte the granulocyte telomere length gap. 38:13 So gray sites which are neutrophils 38:16 or come from the bone marrow circulate for a day. 38:19 And then they're gone. 38:20 They don't divide again into others. Don't get any shorter. 38:23 They're a good reflection of your bone marrow stem cell telomere length 38:26 and of your inherited tumor like the lymphocytes. 38:29 However as you know, fight off release 38:32 from bone marrow and then fight off the infection that they need to 38:35 or the tumor that they need to fight off, and then memory cells are left behind. 38:39 And if that they're challenged again, then they come out again. 38:41 And that's what's happening with CMB, that's happening 38:43 with other herpes viruses, 38:44 and that's what's happening with with other chronic infections. 38:47 And so any time you have a chronic infection that is asking the immune system 38:51 to keep it at bay, you are going to cause telomere attrition. 38:55 And in fact, a nice study was done looking at the number of of herpes viruses 38:59 that you have in addition to CMV from 39:02 one through four EBV, 39:05 HSV two, HHV six, which I think is a big immune stressor 39:09 and and I know you work with that and chronic fatigue, 39:12 the more they have, the much shorter the much faster the telomere attrition is. 39:16 So there's a slope that's relatively shallow, 39:19 about 2.05 killer bases for one herpes virus infection. 39:23 It can steeper for two, even steeper for four and four. 39:26 It's very steep. 39:27 So it's like a 50% steeper slope. 39:29 So you want to try to avoid these, these things. 39:32 That's so I tell patients, you know, the way we're treating Covid right now, 39:36 you should try to keep other pathogens away from you 39:38 when you're young and you're trying to teach your immune system, 39:40 maybe getting a few things to help tolerance. 39:42 But when you're older, you want to stay away from these things. 39:44 Yeah. 39:45 And even, like, you know, at the one, you know, herpes virus one. 39:48 Okay, you get a cold sore, but they find it travels up 39:53 the nerves into the brain and results with Alzheimer's and you. 39:57 And so these things are not benign. 39:59 You know, they're not. No. Yeah. 40:01 That's a nice series of studies 40:03 that's I think just starting to get the recognition 40:05 that you should get that, that HSV one herpes or human herpes virus one is 40:09 is a bad actor for increasing risk of Alzheimer's disease. 40:12 So to me everyone's chronically infected. 40:14 And I think it's so much higher that, you know, 20 years ago 40:19 now I can't go to a party where alone, you know, I'm 40:22 so sick or my brother's so sick or family. 40:26 It's. And he didn't hear that 20 years ago. 40:28 Everyone's these chronic illnesses that just standard medicine 40:32 just doesn't know what to do with. 40:33 And everyone's immune system is shot, you know. 40:38 Yeah. 40:39 So and that's where, you know some of the peptides therapies you talk about. 40:41 You know I was in one alpha and that kind of stuff. 40:43 And I think even potentially growth hormone which can rejuvenate the thyroid. 40:47 But I was in, you know, some smaller studies, you know, the focus 40:51 when you're talking about these chronic immune stressors should be on the host 40:55 on on shoring up their defenses through immune system 40:58 rejuvenation and then through maintaining telomere length 41:01 so the cells can continue to survive, because once they become senescent, 41:04 they can't do their job. 41:05 And not only can they not do their job, I kind of liken them to an old watchdog, 41:10 which not only doesn't go after the burglar, 41:13 but bites the owner and snarling all the time, causing problems. 41:17 So I think that that keeping your immune system youthful is, is, I think, 41:22 not only for fighting off infections and cancers, but also for chronic 41:26 degenerative disease like osteoporosis, cardiovascular disease and Alzheimer's. 41:30 Because of the reduction in inflammation, you know, I follow C reactive protein 41:33 and everybody il6 and everybody people that have a lot of inflammation. 41:38 You have a good lab for aisle six. 41:40 You I mean quest does a good job in lab core. 41:42 They they have a good assay for that because we find it. 41:46 And I think it matters the draw station. 41:48 You know how they you know they hold it. 41:51 And a lot of these like key tests like they'll come out zero you know 41:56 and and they, 41:58 you know, hold them are supposed to be, you know, frozen or whatever mediately. 42:01 And there's that. Now we, we find that's a big problem. 42:04 But yeah FDA is coming after 42:06 I thymus another one because people are using it for Covid. 42:10 And it's such a great Covid 42:13 you know and it's reversible quickly and but God forbid they don't want that. 42:19 And so they're coming after it. 42:21 Yeah. Well you can't get you can't make those claims. 42:23 That's that's the problem without going through the trials. 42:26 But but I mean, you know, look, we know treating patients 42:30 and that's why we're allowed to do off label stuff that, you know, things work. 42:33 That's how medicine progresses through doctors treating patients. 42:37 And you have to look at the risk benefit equation. 42:39 I mean, what's what's the risk benefit equation here. 42:40 It's it's you know, 42:41 we know it's highly in favor of benefit because the risk is so low. 42:45 So yeah, it's not the same thing with Covid. 42:48 Why aren't we giving everyone, you know, vitamin D and zinc? 42:51 And I can see if I have annoyed, 42:54 you know, even ivermectin, even hydroxychloroquine. 42:56 The black helicopters are coming after me. Not. 43:00 And we don't even need the vaccine. 43:02 I no one should be dying from Covid. 43:04 The hospitals aren't giving people anything like the study. 43:07 Just showing people on ventilators. 43:10 They gave them half vitamin D, 5% mortality, the other half without it, 43:14 50% like. 43:16 And there's no downside. 43:18 Yeah, I think that speaks to I mean, look, I just did a talk 43:22 for the Institute of Functional Medicine on, on the, the 43:26 the viral delivery biology, and the effect. 43:29 And what you need to do is to shore shore up the host 43:33 because Covid has shown us that, you know, the age, 43:37 association of Covid is so strong that it's it's 43:40 it's the aging process that debilitated host that's the problem. 43:44 And the cytokine storm coming from the from the 43:47 the senescence associated secretory phenotype. 43:50 But the fact that it happens to younger people is the really interesting thing. 43:55 And what markers of, of of risk are there. 43:58 And I believe that and other authors that are in telomere biology 44:02 that probably these people have short telomeres, the younger people 44:06 that are getting really sick, they either have short telomeres 44:09 or they have much higher accumulation of senescent cells. 44:12 And it may be that that's what's putting them at risk. 44:15 Now, we don't have the data for that. 44:16 But I bet you're right on that because the analogy works out. 44:21 I would I would bet a lot that that you're correct. 44:24 Is there a racial difference in telomere length? 44:27 There? 44:27 Is it in African-Americans has slightly longer telomeres. 44:30 And but that's, that's the only major one. 44:35 But then on top of that, there is the senescence 44:39 T cell stuff comes in because there's a higher incidence of CMV 44:43 in, in in nonwhite ethnic populations in the United States. 44:47 And so that stresses the inheritance that they got. 44:51 And over time, I think their risk increases 44:54 have become so difficult to, you know, so many things. 44:57 They are these people of theirs. 44:58 But why is the real reason, you know, and so there's other things like, 45:02 you know, DNA methylation and omics. 45:06 What. 45:07 So just going back to the, to the, to the biomarkers, the hallmarks of aging, 45:11 me mitochondrial dysfunction, you know, it's all linked. 45:14 You know, I found it fascinating when a paper came out in 2011 45:17 which looked at the effect of short telomeres on, 45:21 mitochondrial biogenesis and mitochondrial efficiency. 45:25 And it's through that master regular, those master regulators, the PG 45:28 one alpha and beta, they are turned down when telomeres get short 45:32 so that you get less mitochondrial biogenesis. 45:34 So keeping children longer helps your mitochondria and vice versa, 45:37 because having efficient mitochondria 45:40 decreases reactive oxygen species, which then don't attack telomeres as much. 45:44 So dividing cells lose about 100 base pairs per year. 45:49 But then while you're dividing, if you have a lot of oxidative stress, 45:54 you know, a telomerase, which I didn't, you know, say for the audience is tag 45:58 tags or repeats of those of those six nucleotides. 46:02 And the jig is very susceptible to free radical damage 46:05 you maybe, maybe use in your practice or have heard of the the DNA damage test, 46:10 which looks at eight hydroxy two deoxy what in in the urine. 46:13 That's those base pairs getting repaired because they've been attacked, 46:17 in the DNA and end up in your urine as a good measure of it. 46:21 So so it's all, you know, what I like about where the field has gone is we now 46:26 have sort of a unified the equivalent in physics of a unified field theory 46:31 in, in aging, where we're really starting to put all the pieces together. 46:35 You know, it's not just this or just that. 46:37 It's like 46:38 the free radical damage affects telomere, that affects epigenetic DNA methylation. 46:43 And then, you know, we're just learning it's all coming together. 46:47 And it's a really fascinating field. 46:50 And then, you know, then we have other hallmarks of aging 46:52 cellular senescence, stem cell exhaustion, and the list goes on. 46:57 Of all these things that you look at as the major things. 46:59 And I actually in my practice, I target the hallmarks of aging. 47:03 I look at ways to measure them. 47:05 You know, we have DNA methylation, we have telomere length. 47:08 We have, you know, ways to look at DNA damage. 47:11 We can look at senescent cells. 47:13 And I focus my therapies on, you know, certain things like flavanols. 47:17 Flavanols can have a beneficial effect. 47:19 Hormone replacement therapy can have another kind of effect 47:21 to try to make your whole blocks of aging as healthy as possible. 47:26 And then put it all together. 47:29 That's at the molecular level. 47:30 Then you look at things like arterial stiffness, pulmonary function. 47:33 These are tried and true biomarkers 47:35 that are that your heart endpoints for mortality and cardiovascular disease. 47:39 Most people don't know that that fev1 they know it's associated with age,
Mitochondria, Biomarkers, and Broader Aging Strategies 47:42 but they don't know that it predicts mortality 25 years later 47:47 from all causes, not just pulmonary and respiratory causes. 47:50 If you have a lower fev1 relative to others in your age group. 47:54 So, so looking at all these different biomarkers, we get to get a feeling 47:57 for what's happening to the aging process. 47:59 And, and, you know, things like 48:03 65, which helps keep telomeres longer. 48:06 It has affected pretty much every system. 48:09 I've talked about cardiovascular disease. 48:11 There's a trial going on right now in the UK, looking at the effect of 48:14 to 65 on senescent cells in people who've had an MI, 48:20 and whether or not through reducing senescent cells 48:24 and the inflammatory response of T regulatory cells, 48:28 will we have a reduction in repeat mix 48:31 because we think that that, and there's very good data showing 48:34 that short telomeres are associated with cardiovascular disease as well. 48:38 So, you know, that's what I like about it is that you're 48:41 you're fixing many things when you're when you're fixing the telomere length. 48:44 We we all know the power of hormones. 48:46 A male post-menopausal and postmenopausal women comes in and, 48:49 you know, you fix your hormones and she, you know, feels a lot of different. 48:52 And it's very gratifying. 48:53 Come after you can 48:54 and I don't want to offend anyone, but a woman is not on estrogen. 48:57 You can pick them out 48:59 like, yeah, I mean it's it's you know, and I've been doing it for 25 years. 49:02 I have patients have been going along and they tell me, you know, 49:06 my girlfriends are saying, you know, they're just looking different 49:09 and feeling different from me, but but you know, so 49:12 but then you want to make sure that their telomere length aren't getting shorter. 49:16 So you want to, you know, optimize all aspects of their aging process. 49:22 And do you have a 49:23 test test for mitochondrial dysfunction? 49:27 I don't really have a great one right now. 49:29 I think that, you know, your you know, your VO2 max might be a beneficial 49:33 one to a certain extent, but that a lot of that is built in in genetics. 49:37 I've been looking for one and yeah, I've been looking for a long time. 49:41 There was the Midas swab, but I don't think it. 49:44 Yeah, it's, you know, it's it's pretty hard. 49:47 Yeah. 49:48 Well, we'll we'll check people's basal metabolic rate, 49:51 which I think, you know, correlates that on mitochondrial function. 49:55 But because so many 49:57 diseases are associated with mitochondrial dysfunction, you know. 50:01 Yeah. 50:01 Most everything disease of aging especially. 50:04 And then let's see was my other oh, Emfs, 50:08 you know anything about emfs and telomeres? 50:11 You know, I don't 50:12 I mean, I've, I've looked for data on that and off the top of my head right now, 50:17 I can't tell you that I found anything, but 50:20 one would think that there's I mean, look, 50:23 low level EMF could be beneficial, potentially. 50:26 You know, some people use it therapeutically. 50:28 We get my screen opened up again. 50:30 But but I don't have any. 50:32 Yeah. 50:33 There's shown that I, I started looking into it very skeptical. 50:36 Like, oh it's got to be safe and and dramatic increase and I, I old six 50:43 and I they activate the calcium 50:46 voltage gated channels and you know that just 50:49 this is in vivo in vitro, right. 50:53 Both. 50:54 And then they also like, once they, they put just the cell phone in the middle 50:58 of a box of rats for nine days, and then they sacrifice them. 51:03 They look they got hippocampal degeneration. 51:06 Wow. It's 51:08 it's crazy. 51:08 I'm I'm I'm worried the more you dig into it, the more you're like, oh my God. 51:12 But that's a whole nother. Another topic. 51:15 What what were some pearls like what are your favorite treatments? 51:19 I know you know 65 of course other things. 51:22 What are your like top five things or 51:27 I mean, for for me, in my practice I do a lot of hormone optimization. 51:30 I don't think that that that people 51:34 without sort of more optimal hormones 51:37 are going to enjoy life as much as people 51:40 that don't have optimal as people that do tend to have optimal hormone levels. 51:43 I mean, I do use to 65 a lot. 51:46 I have a whole pack of, of, of supplements that I think, 51:50 you know, the omega three fatty acids. I think are very, very important. 51:52 There's a lot more coming out of that, particularly in Alzheimer's disease. 51:56 And then, you know, the plasma allergens, which you you may have seen some of that 52:00 work that's been done. 52:02 We're doing good now. 52:04 We're, you know, you're looking at, 52:07 you know, happily genotype and risk being abrogated 52:11 or almost completely mitigated by, by having good plasma allergy levels. 52:15 So I try to 52:16 I mean, just like your Boston heart out there in the corner, 52:18 I do the Boston Heart Essential fatty acid analysis. 52:20 And I have everybody want to get their omega six index you optimal range. 52:24 So I use I use them if they don't get it through fish. 52:27 You know I get it through through the fish oil and the margins. 52:31 I mean, I have some here. I like sage. 52:33 And then I've also heard the oh, 52:35 they just get broken down, you know, so plasma things do. 52:39 But but what what you're seeing there is a precursor that then makes it 52:43 through the gut and then is it is used to build plasma allergens. 52:46 At least that's how it's been explained to me. 52:49 I've done my first baseline. 52:51 I have to do some. 52:51 The follow up wants to see, you know, whether or not it's effective. 52:54 But I'm just that's an area just in general fatty acids. 52:58 I think I'm plasma allergens are, you know, an area 53:02 that I think is really up and coming for data supporting, 53:05 you know, optimizing those levels for, for healthy aging and disease prevention. 53:10 I would say, you know, we've talked about senescence of the immune system. 53:13 You know, for people that can't necessarily send, 53:17 their stuff 53:18 to UCLA, where I send it for looking at naive T cells and senescent cells, 53:22 which are specific markers CD 95 and CD 28. 53:27 If you have a CD4 to CD8 ratio, which is available at, 53:30 you know, quest or lab or any lab at those, 53:31 you know, lymphocyte subset panel, if it's less than one, there's a there's a 53:35 there's a good body of data that shows particularly in older 53:39 individuals, those are 80 and above and then even 60 and above that 53:44 they're starting to collect more senescent cells 53:47 because the denominator is the CD8 and it's the is the suppressor 53:50 or cytotoxic T cells that get senescent, not necessarily the helper cells as much. 53:55 So the top stays fairly stable. 53:57 There's the CD4 but you get this accumulation. 54:00 They don't die and go away. 54:01 And it's not because you have a lot of healthy senescence suppressed, 54:04 a lot of healthy suppressor cells. 54:05 You have the accumulation, you know of them. 54:08 And if that gets below one, then you really want to look at, 54:11 you know, trying to I would then measure the telomere length in that patient. 54:15 And and if they're not you know, if they're doing they're not doing everything 54:18 that you can do for a lifestyle standpoint, then do it. 54:21 Quit smoking, make sure because they're it's significant 54:24 increased risk of of disease and mortality. 54:28 When that ratio gets inverted it's normally around 2 to 2 and a half. 54:31 You know when it gets below 54:32 one things things get really pretty bad because I'm thinking of the line patient. 54:36 We see their CD age drop much more than their C4 drop. 54:41 But with, you know, 54:43 the total CDA population. 54:45 Yeah, I'm not sure. 54:48 But I mean that I can kind of be sure I'm not sure about that because 54:53 what would happen, I would think, is that you would increase the number 54:56 of senescent cells because the liver is trying to be fought off by that. 54:59 But and the patients that I have come in, I see, like I haven't a number, 55:02 that they have large accumulations of senescent. 55:04 So just to give you an idea, 55:06 I mean, you typically have zero, six and T cells when you're born. 55:09 And then, you know, 55:10 they thought that you used to accumulate that with just the aging process. 55:14 But it's really whether it's really your viral load in particular CMB 55:18 that caused that. 55:19 And also other as we talked about other immune stressors. 55:22 So I have patients that are in their 60s that have, you know, 55:25 20, 30 55:27 senescent cells, you know, on, on, on a measurement. 55:30 And then I have patients who have 800 55:33 and that's like 75 to 80% of their CD8 55:37 compartment is senescent and secreting all sorts testes. 55:42 But yes. 55:44 So that's the that's the that's the Cd28 negative is the senescent cells 55:48 that you can get at UCLA. 55:49 And you can get it through your age. 55:51 You know, if you go to Fisher age.com 55:52 and have a licensee, you can get it through that or to Sciences 55:56 also offers that@sciences.com to to to get the test or UCLA as well. 56:01 But as I said the less the you know the one that can go through insurance 56:05 and is less expensive is to just look at the CD4 to CD8 ratio. 56:09 And if it's if it's under one and you, you almost assuredly 56:12 have a higher accumulation of senescent cells. 56:16 And how about CD 16? 56:19 You mean 56:20 that's a there's not a CD 16 or CD 19, which is the B7 city? 56:25 I remember because I haven't done my labs in a long time. 56:27 If I was a solo when I was sick. 56:29 56 CD 16 you're talking about for the Natural Killer Cells. 56:34 That's. Yeah. 56:35 No, I don't see 56 or C 57, but anyways, entry it's what also. 56:41 So immunosuppressants suppress for auto immunity, but 56:44 they tend to be really low. 56:47 But in some patients as weird a subset of patients. 56:51 Yeah. I don't measure that one. 56:53 We look at the 56:53 we look at the natural killer cells, which is the CD 56 to 16 positive. 56:57 And then we look at the, the CB 48. 57:01 And did you measure function. 57:03 So it's it's the lymphocyte subsets because there's a there's a very large 57:07 body of data showing the association between those and autoimmune 57:10 disorders, viral load mortality. 57:14 Functional assays would be interesting. 57:16 There haven't been as many studies with those. 57:18 But you know, 57:19 you get very good information in just looking at the markers on the idea. 57:23 Yeah. 57:23 And for instance, like natural killer cell function, you know, it's a hallmark 57:27 of chronic fatigue syndrome. 57:28 And like that about 70% are low. 57:31 Next killer cell function about 30% are low natural some number. 57:36 There's a lot of them like Gerd. Yeah. 57:37 So that's a not working. 57:39 The problem is a quest. 57:41 Does the the function and quests so difficult to deal with. 57:45 They they're almost of course much easier to deal with. 57:49 But they're that other test 57:51 couple other tricky tests that we like 57:55 quest as a better job. 57:56 But overall quest is a pain. 57:58 Yes, but 58:00 yeah, let me know for the last two years and try to become a true national lab. 58:04 And they're just not they're not there. 58:06 All right. 58:06 Yeah, yeah, yeah. 58:08 I'd love to see someone else come on. 58:10 You know, come on line and let's see. 58:12 You wrote a number of papers on the 65. 58:16 And so that's that's a core treatment. 58:20 And, you know, like hormones you do thyroid, by the way. You. 58:24 Oh yeah. Yeah. That's fibroids. 58:26 I mean, what you were talking about with getting women pregnant with the T3, 58:29 I mean, it's it's very gratifying 58:31 when their, you know, their, their fertility doctor. 58:33 So I mean, if I were a tester, normal and, and, you know, they've done three rounds 58:36 and you get your T3, you know, about 3.8 and all of a sudden they're pregnant. 58:41 So I do I do I do a fair amount with thyroid. 58:43 I find it to be a. Yeah. 58:44 And that's like I spent most of my medical work 58:47 convincing people that it's not reliable, you know, because all these sick 58:52 patients, they get suppressed, you know, hypothalamic pituitary thyroid axis. 58:56 And they're not making PSA. 58:58 And but that's just the way it's an easy test. 59:02 And, you know, a controversial someone working on a NASA that will show that. 59:08 But we're out for 15 years and I get to a certain point something happens. 59:14 So now I'm going to some big guys and see if I can get that, but 59:19 kind of prove that all these people with normal TSH
Statins, Personalized Medicine, and Closing Remarks 59:22 is, you know, and they come in and normal teenage 59:25 and there we check their basal metabolic rate and super low and their 59:30 their basically relaxation phase of their, of their reflex super low. 59:34 And their pulse is like 50 and they're gaining weight like crazy. 59:39 And then you give some thyroid and that's a surprise 59:40 because it's like, oh, they're hypothyroid. 59:43 And like, oh, they can't get a pulse is 48. 59:46 And the freezing cold and yeah. Anyways. 59:49 But another thing and that's thyroid has lots of increased mitochondrial function. 59:54 And and there's so many things. 59:57 Yeah absolutely I mean it's just you know it needs to be optimized as well. 1:00:00 I mean, I've 1:00:03 the thyroid analogs I've been to look at, looked at to lower cholesterol. 1:00:06 I mean, we all know the cholesterol shoots up in your hypothyroid. 1:00:09 And patients that are, that are have good thyroid function 1:00:12 and their cholesterol can come down quite significantly. 1:00:14 So yeah, I mean it's like the safest way or the star report, 1:00:18 largest study ever done an antidepressant showed 1:00:20 that T3 was a better present than any of the left side of it. 1:00:24 But it didn't make the abstract because they didn't mean for part of the study. 1:00:28 You know. 1:00:29 Oh yeah, you have to deal with that in our field. 1:00:31 Well, there's so much bias. 1:00:33 And so that's this, you know, basically driving me crazy. 1:00:37 But yeah, they are your whole program sounds very interesting. 1:00:40 And and looking at all these things I think is the key 1:00:44 to so many ways of approaching so many illnesses. 1:00:48 And I think that's the problem with modern medicine is you get sent to, 1:00:52 you know, gas or allergies, but it has, you know, just 1:00:55 and you don't go until something's really bad, right? 1:00:59 You know, and and people say, 1:01:02 well, I can't, you know, out of network, you know. 1:01:05 And how much is it worth not being in a nursing home for 20 years, 1:01:11 living longer, being longer with your kids and your grandkids, and you're 1:01:14 having a better quality of life. 1:01:16 You can't put a price on that. 1:01:18 And you know, when I had Lyme and was bedbound, you know, 1:01:21 I would trade everything for just take everything. 1:01:26 Just want to be healthy because you can't doesn't matter how much money you have 1:01:30 when you don't have your health. 1:01:32 And so I think you're doing some amazing work and helping so many people, 1:01:37 because we take it for granted that we're healthy until we're not. 1:01:41 And it happens, you know. Yeah. 1:01:44 And the key, the key thing that did up what drive home is that 1:01:48 you can measure how healthy you are, you know, and you may not be as healthy 1:01:53 as you think you are even though you feel good, because a lot of this stuff 1:01:56 smolders at a subclinical level until it breaks through. 1:02:00 And the idea is to pick it up 10 to 15 years before that. 1:02:03 And that's why we look at. 1:02:04 Yeah, because when you can do something about it. 1:02:06 Yeah. Exactly. 1:02:08 There's a whole phrase is that, you know, at first 1:02:10 the disease is easy to cure but difficult to diagnose. 1:02:15 But as time passes, it becomes easy to diagnose but different, difficult to cure. 1:02:19 And it's like you're really 1:02:22 and, that's a good a good summary right there. 1:02:25 Hey, I think this is fascinating stuff. 1:02:28 I think you're doing great work. 1:02:30 And, you know, I think the way showing people all these different, 1:02:35 you know, markers, I think is, is just huge. 1:02:39 And you're very obviously evidence based DNA. 1:02:43 And as patients, you're proving to the patient 1:02:46 this therapy works, not just hey, take this, one question I want to ask. 1:02:50 What's your thought on statins? 1:02:53 You know, I think that statins interestingly, look, there's the world. 1:02:56 There's kind of it's big. 1:02:57 It's gotten really divided. 1:02:59 And there's are people that approach that and people are anti. 1:03:01 Everything becomes like a political argument right. 1:03:04 Yeah I think that the statins my quick take on it is that in certain 1:03:09 correct populations they save lives. 1:03:12 I don't think there's strong data for that. 1:03:14 They're overprescribed in people that don't need them. 1:03:17 And you know, most people tolerate them, but a lot of people don't tolerate them. 1:03:20 Interestingly, statins do have very mild telomerase activity. 1:03:24 And maybe one of the reasons that they're effective by 1:03:27 turning on telomerase and likely to longer, that's part of the work 1:03:30 that's being done by Kim Spear adopted this out in the UK in the same way 1:03:33 that's running that trial that I talked about with telomere biology. 1:03:36 But I think that the problem is, is that 1:03:40 the cardiologists, in turn, this sort of 1:03:42 don't give patients a chance and say, look, you can get your cholesterol down 1:03:46 if you make these changes in your diet, get exercise and do all these things. 1:03:50 And I have patients with cholesterol of 300 1:03:52 because everything else is working well. 1:03:54 They've got clean corners and they're 75 years old. 1:03:56 So you know that person doesn't need a standard person 1:04:00 with a cholesterol of 200 with the coronary calcium 1000. 1:04:03 I think, you know, you're probably it's malpractice 1:04:05 not to give them a statin at that point. 1:04:06 If they're not doing everything else because of the anti inflammation, 1:04:09 probably doesn't have that much to do with the cholesterol. Yeah. 1:04:11 And I think the whole cholesterol theory of heart disease is 1:04:14 you know it's getting its legs knocked out over and over. 1:04:17 And it isn't inflammatory. 1:04:19 But also it's a it's a mitochondrial inhibitor you know. 1:04:23 Right. Yeah. So yeah and that's the problem. Exactly. 1:04:25 So I think there's a better way. You know, to to do it. 1:04:28 You know in certain patients, you know for instance, the study came out and showed 1:04:33 basically it seems the ideal patient 1:04:36 diabetic patients with heart disease. 1:04:39 He showed an increased mortality like, okay, it doesn't work for these people. 1:04:44 Why? And I think any time you try to give it to everyone, you know, 1:04:47 they want to put it in the water. 1:04:48 That's when you get into trouble. 1:04:50 That was a big problem with the polypill back in the back in the day when they 1:04:53 when they put a, a beta blocker, a statin, an Ace inhibitor, aspirin. 1:04:57 I think one of the thing in, in a pill 1:05:01 that's the opposite of personalized medicine, 1:05:03 you would probably get an overall beneficial effect on mortality, 1:05:06 but you'd have a lot of people being treated, don't you? 1:05:07 Be treated have side effects. 1:05:09 And if one is really, you know, the where medicine is going, 1:05:12 because we're all very different in many different ways. 1:05:14 And unless you're exactly like the average person in that large 1:05:17 clinical trial, the data may not be applicable to you. 1:05:20 Yeah. And it's totally true. 1:05:22 And I tell patients, look, we go by the studies, but you're not a study. 1:05:25 You're a person. 1:05:27 And and they usually take people that don't have anything else. 1:05:32 And what. 1:05:33 So they're a rare breed you know finding those people. 1:05:36 And and so we're, you know, doing studies and thinking like, 1:05:39 how do you find a healthy person, you know, 1:05:43 and it's everyone's exposed to toxic pesticides, plastic stress, you know, 1:05:48 all this stuff and like, you know, BPA, you know, and all the pollutants. 1:05:53 But chronic infections like, I don't know, there's 1:05:56 healthy people out there to do that control. 1:06:00 But yeah, a fascinating stuff. 1:06:02 I, I, I think this is great. 1:06:04 I think you're doing such a great service and happy to help get get the word out. 1:06:09 I'm going to give you a buzz this week and and about your software about, sure. 1:06:15 Yeah. I'll be around. Absolutely. Great. Have you. 1:06:17 Thanks for having thanks for having me. All right. Thanks so much. 1:06:20 All right. 1:06:20 Take your hey day. 1:06:21 Thank you for tuning in to Doctor Talks. 1:06:23 We hope today's episode has enlightened 1:06:25 and inspired you on your path to optimal health. 1:06:28 Each day is a new opportunity to make choices that empower your well-being. 1:06:33 For more insights and strategies, subscribe to our podcast 1:06:36 and visit our website WW di Doctor talk.com. 1:06:42 Stay connected, stay healthy and join us next time on Doctor Talks. 1:06:47 Real talks from real doctors on the issues that matter to you most.
Comments